Aclarion (NASDAQ:ACON) Price Target Lowered to $1.30 at Ascendiant Capital Markets

Aclarion (NASDAQ:ACON) had its target price decreased by Ascendiant Capital Markets from $1.50 to $1.30 in a research note released on Wednesday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Aclarion Price Performance

Shares of NASDAQ ACON opened at $0.18 on Wednesday. Aclarion has a 12-month low of $0.16 and a 12-month high of $7.40. The company has a 50-day moving average of $0.18 and a 200 day moving average of $0.24.

Hedge Funds Weigh In On Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new stake in shares of Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion at the end of the most recent quarter. 7.52% of the stock is owned by hedge funds and other institutional investors.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.